Movement Alert|Iovance Biotherapeutics, Inc. Intraday Rise 8.52% in Regular Trading, Earnings Beat Renewed Focus on Commercial Execution

Market Focus11-09

On November 9, Iovance Biotherapeutics, Inc. rose 8.52% in Regular Trading, trading at $8.7577/share, with turnover of $28.6836 million.

The move followed a recent quarterly report that beat expectations on both earnings and revenue, prompting the market to refocus on the company’s commercialization progress.

For the quarter ended September 30, the company reported a loss of $0.05 per share, better than consensus expectations of a $0.08 to $0.09 loss, while revenue reached $121.5 million versus expectations of about $116 million. Revenue also increased from $67.5 million a year earlier, indicating continued product uptake and a narrowing loss profile. However, the company maintained full-year product revenue guidance at $410 million to $420 million, rather than raising it again after the sizable increase announced in late September. The latest rise suggests investors are reacting positively to the earnings beat itself despite a more measured view on additional near-term guidance upside.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment